PURPOSE: Activation of tubular epithelial cells by transforming growth factor-beta (TGF-beta) plays an important role in the pathogenesis of renal tubulointerstitial fibrosis. We developed a renally accumulating conjugate of a TGF-beta type-I receptor kinase inhibitor (TKI) and evaluated its efficacy in vitro and in vivo. METHODS: TKI was conjugated to the protein Lysozyme (LZM) via a platinum-based linker. TKI-LZM was evaluated in human tubular cells (HK-2) for its anti-fibrotic activity. Plasma, kidney and urine drug levels after a single intravenous dose of TKI-LZM in rats were determined by HPLC or immunodetection. Anti-fibrotic effects of TKI-LZM were examined in the unilateral ureteral obstruction (UUO) model. RESULTS: TKI-LZM conjugate was successfully synthesized at an 1:1 drug/carrier ratio, and inhibited TGF-beta1-induced procollagen-1alpha1 gene expression in HK-2 cells. In vivo, TKI-LZM accumulated rapidly in tubular cells and provided a local depot for 3 days. Interestingly, a single dose of TKI-LZM inhibited the activation of tubular cells and fibroblasts in UUO rats and reduced renal inflammation. In contrast, free TKI at an equimolar (low) dosage exhibited little effects. CONCLUSIONS: Inhibition of TGF-beta signaling by local drug delivery is a promising antifibrotic strategy, and demonstrated the important role of tubular activation in renal fibrosis.
PURPOSE: Activation of tubular epithelial cells by transforming growth factor-beta (TGF-beta) plays an important role in the pathogenesis of renal tubulointerstitial fibrosis. We developed a renally accumulating conjugate of a TGF-beta type-I receptor kinase inhibitor (TKI) and evaluated its efficacy in vitro and in vivo. METHODS: TKI was conjugated to the protein Lysozyme (LZM) via a platinum-based linker. TKI-LZM was evaluated in human tubular cells (HK-2) for its anti-fibrotic activity. Plasma, kidney and urine drug levels after a single intravenous dose of TKI-LZM in rats were determined by HPLC or immunodetection. Anti-fibrotic effects of TKI-LZM were examined in the unilateral ureteral obstruction (UUO) model. RESULTS: TKI-LZM conjugate was successfully synthesized at an 1:1 drug/carrier ratio, and inhibited TGF-beta1-induced procollagen-1alpha1 gene expression in HK-2 cells. In vivo, TKI-LZM accumulated rapidly in tubular cells and provided a local depot for 3 days. Interestingly, a single dose of TKI-LZM inhibited the activation of tubular cells and fibroblasts in UUO rats and reduced renal inflammation. In contrast, free TKI at an equimolar (low) dosage exhibited little effects. CONCLUSIONS: Inhibition of TGF-beta signaling by local drug delivery is a promising antifibrotic strategy, and demonstrated the important role of tubular activation in renal fibrosis.
Authors: Juswinder Singh; Claudio E Chuaqui; P Ann Boriack-Sjodin; Wen Cherng Lee; Timothy Pontz; Michael J Corbley; H-Kam Cheung; Robert M Arduini; Jonathan N Mead; Miki N Newman; James L Papadatos; Scott Bowes; Serene Josiah; Leona E Ling Journal: Bioorg Med Chem Lett Date: 2003-12-15 Impact factor: 2.823
Authors: Anne-Charlotte de Gouville; Valerie Boullay; Gael Krysa; Julia Pilot; Jean-Marie Brusq; Florence Loriolle; Jean-Michel Gauthier; Stephen A Papworth; Alain Laroze; Françoise Gellibert; Stephane Huet Journal: Br J Pharmacol Date: 2005-05 Impact factor: 8.739
Authors: Eugene T Grygielko; William M Martin; Christopher Tweed; Peter Thornton; John Harling; David P Brooks; Nicholas J Laping Journal: J Pharmacol Exp Ther Date: 2005-03-15 Impact factor: 4.030
Authors: Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell Journal: Annu Rev Immunol Date: 2006 Impact factor: 28.527
Authors: Amélie Dendooven; David A Ishola; Tri Q Nguyen; Dionne M Van der Giezen; Robbert Jan Kok; Roel Goldschmeding; Jaap A Joles Journal: Int J Exp Pathol Date: 2010-08-27 Impact factor: 1.925
Authors: Jai Prakash; Martin H de Borst; Marie Lacombe; Frank Opdam; Pieter A Klok; Harry van Goor; Dirk K F Meijer; Frits Moolenaar; Klaas Poelstra; Robbert J Kok Journal: J Am Soc Nephrol Date: 2008-07-23 Impact factor: 10.121
Authors: M E M Dolman; Stefan Harmsen; Ebel H E Pieters; Rolf W Sparidans; Marie Lacombe; Bálint Szokol; László Orfi; György Kéri; Gert Storm; Wim E Hennink; Robbert J Kok Journal: Int J Nanomedicine Date: 2012-01-31
Authors: Marike Marjolijn van Beuge; Jai Prakash; Marie Lacombe; Eduard Post; Catharina Reker-Smit; Leonie Beljaars; Klaas Poelstra Journal: PLoS One Date: 2013-02-18 Impact factor: 3.752